Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2019

Open Access 01-12-2019 | Stroke | Research article

Ischemic stroke risk estimation in patients without oral anticoagulation: an observational cohort study based on secondary data from Germany

Authors: Felix S. Wicke, Martin A. Schaller, Kateryna Karymova, Martin Beyer, Beate S. Müller

Published in: BMC Cardiovascular Disorders | Issue 1/2019

Login to get access

Abstract

Background

Oral anticoagulants can cause potentially serious adverse events. Therefore, before prescribing oral anticoagulants for ischemic stroke prevention in patients with atrial fibrillation (AF), stroke risk assessment is required to identify patients that are likely to benefit from treatment. Current guidelines recommend the CHA2DS2-VASc-score for stroke risk assessment. The CHA2DS2-VASc-score is based on observational studies from different treatment settings and countries. As ischemic stroke risk differs by setting and region, the aim of this study is to estimate ischemic stroke risk (stratified by the CHA2DS2-VASc-score) for a broadly representative population with AF from southern Germany and compare them to results from previous studies.

Methods

The study design is a retrospective cohort study on patients with atrial fibrillation based on secondary data. We calculated CHA2DS2-VASc-score based on patient’s diagnoses recorded in the year 2014 and assessed outcomes in 2015–2016. The primary outcome is hospitalization for ischemic stroke. The secondary outome is hospitalizations for any thromboembolic event, including ischemic stroke, transient ischemic attack, peripheral arterial embolism, pulmonary embolism, and mesenterial embolism. We estimated the incidence rates of the outcomes (and corresponding 95%-confidence intervals) stratified by CHA2DS2-VASc-score.

Results

The primary endpoint occurred in 961 of the 30,299 patients constituting the study population, resulting in a total incidence rate of 2.2 per 100 person-years. The secondary endpoint occurred in 1553 patients (3.6 per 100 person-years). Ischemic stroke rates stratified by the CHA2DS2-VASc-score tended to be lower than those reported previously. Thromboembolic event rates stratified tended to be similar to those reported previously.

Conclusions

Our results show that the performance of the CHA2DS2-VASc-score differs in the German population, as compared to internationally published data, with an overall trend towards lower risk of ischemic stroke in uncoagulated patients with AF. These results should not be practice changing, but they emphasize that stroke risk estimation in patients with atrial fibrillation should be further refined.
Literature
1.
go back to reference Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67.CrossRef Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67.CrossRef
2.
go back to reference Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2005; (3):CD001927. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2005; (3):CD001927.
3.
go back to reference Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962.CrossRef Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962.CrossRef
4.
go back to reference January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199–267.PubMedPubMedCentral January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199–267.PubMedPubMedCentral
5.
go back to reference January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the Management of Patients with Atrial Fibrillation. Circulation. 2019:CIR0000000000000665. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the Management of Patients with Atrial Fibrillation. Circulation. 2019:CIR0000000000000665.
6.
go back to reference Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72.CrossRef Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72.CrossRef
7.
go back to reference Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study. Eur Heart J. 2012;33(12):1500–10.CrossRef Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study. Eur Heart J. 2012;33(12):1500–10.CrossRef
8.
go back to reference van den Ham HA, Klungel OH, Singer DE, Leufkens HGM, van Staa TP. Comparative performance of ATRIA, CHADS2, and CHA2DS2-VASc risk scores predicting stroke in patients with atrial fibrillation. Results From a National Primary Care Database J Am Coll Cardiol. 2015;66(17):1851–9.PubMed van den Ham HA, Klungel OH, Singer DE, Leufkens HGM, van Staa TP. Comparative performance of ATRIA, CHADS2, and CHA2DS2-VASc risk scores predicting stroke in patients with atrial fibrillation. Results From a National Primary Care Database J Am Coll Cardiol. 2015;66(17):1851–9.PubMed
9.
go back to reference Kim T-H, Yang P-S, Kim D, Yu HT, Uhm J-S, Kim J-Y, et al. CHA2DS2-VASc score for identifying truly low-risk atrial fibrillation for stroke: a Korean Nationwide cohort study. Stroke. 2017;48(11):2984–90.CrossRef Kim T-H, Yang P-S, Kim D, Yu HT, Uhm J-S, Kim J-Y, et al. CHA2DS2-VASc score for identifying truly low-risk atrial fibrillation for stroke: a Korean Nationwide cohort study. Stroke. 2017;48(11):2984–90.CrossRef
10.
go back to reference Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc. 2013;2(3):e000250.CrossRef Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc. 2013;2(3):e000250.CrossRef
11.
go back to reference Olesen JB, Lip GYH, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide cohort study. BMJ. 2011;342:d124.CrossRef Olesen JB, Lip GYH, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide cohort study. BMJ. 2011;342:d124.CrossRef
12.
go back to reference Allan V, Banerjee A, Shah AD, Patel R, Denaxas S, Casas J-P et al. Net clinical benefit of warfarin in individuals with atrial fibrillation across stroke risk and across primary and secondary care. Heart 2017; 103(3):210–218. Available from: URL: https://heart.bmj.com/content/103/3/210. Allan V, Banerjee A, Shah AD, Patel R, Denaxas S, Casas J-P et al. Net clinical benefit of warfarin in individuals with atrial fibrillation across stroke risk and across primary and secondary care. Heart 2017; 103(3):210–218. Available from: URL: https://​heart.​bmj.​com/​content/​103/​3/​210.
13.
go back to reference Quinn GR, Severdija ON, Chang Y, Singer DE. Wide variation in reported rates of stroke across cohorts of patients with atrial fibrillation. Circulation. 2017;135(3):208–19.CrossRef Quinn GR, Severdija ON, Chang Y, Singer DE. Wide variation in reported rates of stroke across cohorts of patients with atrial fibrillation. Circulation. 2017;135(3):208–19.CrossRef
14.
go back to reference Zhou X-H, Obuchowski NA, McClish DK. Statistical methods in diagnostic medicine. 2., Auflage. New York, NY: John Wiley & Sons; 2011. (Wiley Series in Probability and Statistics). Zhou X-H, Obuchowski NA, McClish DK. Statistical methods in diagnostic medicine. 2., Auflage. New York, NY: John Wiley & Sons; 2011. (Wiley Series in Probability and Statistics).
16.
go back to reference Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.CrossRef Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.CrossRef
17.
go back to reference Pisters R, Lane DA, Nieuwlaat R, de VCB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey. Chest. 2010;138(5):1093–100.CrossRef Pisters R, Lane DA, Nieuwlaat R, de VCB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey. Chest. 2010;138(5):1093–100.CrossRef
18.
go back to reference Friberg L, Skeppholm M, Terént A. Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. J Am Coll Cardiol. 2015;65(3):225–32.CrossRef Friberg L, Skeppholm M, Terént A. Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. J Am Coll Cardiol. 2015;65(3):225–32.CrossRef
19.
go back to reference Bikdeli B, Abou Ziki MD, Lip GYH. Pulmonary embolism and atrial fibrillation: two sides of the same coin? A systematic review. Semin Thromb Hemost. 2017;43(8):849–63.CrossRef Bikdeli B, Abou Ziki MD, Lip GYH. Pulmonary embolism and atrial fibrillation: two sides of the same coin? A systematic review. Semin Thromb Hemost. 2017;43(8):849–63.CrossRef
20.
go back to reference Flegel KM. When atrial fibrillation occurs with pulmonary embolism, is it the chicken or the egg? vol. 160; 1999. p. 1181–2. Flegel KM. When atrial fibrillation occurs with pulmonary embolism, is it the chicken or the egg? vol. 160; 1999. p. 1181–2.
21.
go back to reference Ogren M, Bergqvist D, Eriksson H, Lindblad B, Sternby NH. Prevalence and risk of pulmonary embolism in patients with intracardiac thrombosis: a population-based study of 23 796 consecutive autopsies. Eur Heart J. 2005;26(11):1108–14.CrossRef Ogren M, Bergqvist D, Eriksson H, Lindblad B, Sternby NH. Prevalence and risk of pulmonary embolism in patients with intracardiac thrombosis: a population-based study of 23 796 consecutive autopsies. Eur Heart J. 2005;26(11):1108–14.CrossRef
22.
go back to reference van Langevelde K, Srámek A, Vincken PWJ, van Rooden J-K, Rosendaal FR, Cannegieter SC. Finding the origin of pulmonary emboli with a total-body magnetic resonance direct thrombus imaging technique. Haematologica. 2013;98(2):309–15.CrossRef van Langevelde K, Srámek A, Vincken PWJ, van Rooden J-K, Rosendaal FR, Cannegieter SC. Finding the origin of pulmonary emboli with a total-body magnetic resonance direct thrombus imaging technique. Haematologica. 2013;98(2):309–15.CrossRef
23.
go back to reference Di Nisio M, van Es N, Büller HR. Deep vein thrombosis and pulmonary embolism. Lancet. 2016;388(10063):3060–73.CrossRef Di Nisio M, van Es N, Büller HR. Deep vein thrombosis and pulmonary embolism. Lancet. 2016;388(10063):3060–73.CrossRef
25.
go back to reference Schnabel RB, Wilde S, Wild PS, Munzel T, Blankenberg S. Atrial fibrillation: its prevalence and risk factor profile in the German general population. Dtsch Arztebl Int. 2012;109(16):293–9.PubMedPubMedCentral Schnabel RB, Wilde S, Wild PS, Munzel T, Blankenberg S. Atrial fibrillation: its prevalence and risk factor profile in the German general population. Dtsch Arztebl Int. 2012;109(16):293–9.PubMedPubMedCentral
26.
go back to reference Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R, et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace. 2013;15(4):486–93.CrossRef Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R, et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace. 2013;15(4):486–93.CrossRef
27.
go back to reference Asinger RW, Shroff GR, Simegn MA, Herzog CA. Anticoagulation for Nonvalvular atrial fibrillation: influence of epidemiologic trends and clinical practice patterns on risk stratification and net clinical benefit. Circ Cardiovasc Qual Outcomes. 2017;10(9). Asinger RW, Shroff GR, Simegn MA, Herzog CA. Anticoagulation for Nonvalvular atrial fibrillation: influence of epidemiologic trends and clinical practice patterns on risk stratification and net clinical benefit. Circ Cardiovasc Qual Outcomes. 2017;10(9).
28.
go back to reference Hernandez I, Saba S, Zhang Y. Geographic variation in the use of oral anticoagulation therapy in stroke prevention in atrial fibrillation. Stroke. 2017;48(8):2289–91.CrossRef Hernandez I, Saba S, Zhang Y. Geographic variation in the use of oral anticoagulation therapy in stroke prevention in atrial fibrillation. Stroke. 2017;48(8):2289–91.CrossRef
29.
go back to reference Steinberg BA, Gao H, Shrader P, Pieper K, Thomas L, Camm AJ, et al. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. Am Heart J. 2017;194:132–40.CrossRef Steinberg BA, Gao H, Shrader P, Pieper K, Thomas L, Camm AJ, et al. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. Am Heart J. 2017;194:132–40.CrossRef
30.
go back to reference Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. The stroke prevention in atrial fibrillation Investigators. Ann Intern Med. 1992;116(1):6–12.CrossRef Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. The stroke prevention in atrial fibrillation Investigators. Ann Intern Med. 1992;116(1):6–12.CrossRef
31.
go back to reference Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med. 1998;158(12):1316–20.CrossRef Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med. 1998;158(12):1316–20.CrossRef
32.
go back to reference Hijazi Z, Oldgren J, Siegbahn A, Granger CB, Wallentin L. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J. 2013;34(20):1475–80.CrossRef Hijazi Z, Oldgren J, Siegbahn A, Granger CB, Wallentin L. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J. 2013;34(20):1475–80.CrossRef
Metadata
Title
Ischemic stroke risk estimation in patients without oral anticoagulation: an observational cohort study based on secondary data from Germany
Authors
Felix S. Wicke
Martin A. Schaller
Kateryna Karymova
Martin Beyer
Beate S. Müller
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2019
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-019-1074-7

Other articles of this Issue 1/2019

BMC Cardiovascular Disorders 1/2019 Go to the issue